In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians in the early detection and overall management of HCC, and his clinical experience with PIVKA-II. …
Cancer Type: Liver
APASL 2023 Taiwan Symposium
Watch the APASL 2023 symposium recording to hear experts share key updates on HCC surveillance, diagnosis, uHCC management and adj HCC systemic treatment. …
Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region
A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements….
Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in China.
Leung MK, Ko M, Chen J, Garay OU, Leung B, Chow C, Li E, Wu JTK, Yuen MF, Zheng Q…